Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 20/20 | 0.76 |
| ▸ | PRKCD | Q05655 | 20/20 | 0.76 |
| ▸ | LYN | P07948 | 8/20 | 0.69 |
| ▸ | LCK | P06239 | 2/20 | 0.65 |
| ▸ | PRKCH | P24723 | 2/20 | 0.65 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.65 |
| ▸ | FYN | P06241 | 1/20 | 0.65 |
| ▸ | HCK | P08631 | 1/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | PRKCB | P05771 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951734 | 0.90 | PRKCQ (0.73) | PRKCQPRKCDLYNLCKPRKCH | |
| SCHEMBL4117744 | 0.88 | PRKCQ (0.71) | PRKCQPRKCDLYNLCKPRKCH | |
| SCHEMBL4949250 | 0.87 | PRKCQ (0.75) | PRKCQPRKCDLYNLCKPRKCH | |
| SCHEMBL4950415 | 0.86 | PRKCQ (0.71) | PRKCQPRKCDLYNLCKPRKCH | |
| SCHEMBL4111230 | 0.86 | PRKCQ (1.00) | PRKCQPRKCDLYNLCKPRKCH | |
| SCHEMBL5525685 | 0.86 | PRKCQ (0.82) | PRKCQPRKCDLYNLCKPRKCH | |
| SCHEMBL5518907 | 0.86 | PRKCQ (0.82) | PRKCQPRKCDLYNLCKPRKCH | |
| SCHEMBL5520971 | 0.86 | PRKCQ (0.85) | PRKCQPRKCDLYNLCKPRKCH | |
| SCHEMBL5520320 | 0.86 | PRKCQ (0.82) | PRKCQPRKCDLYNLCKPRKCH | |
| SCHEMBL5518063 | 0.85 | PRKCQ (0.83) | PRKCQPRKCDLYNLCKPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066675-A1 | PROCESS FOR THE PREPARATION OF 4-HYDROXYTHIENO[2,3-B]PYRIDINE-5-CARBONITRILES | Wyeth (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008039414-A1 | PROCESS FOR THE PREPARATION OF 4-HYDROXYTHIENO[2,3-B]PYRIDINE-5-CARBONITRILES | WYETH (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080076926-A1 | Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles | WYETH | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076926-A1 | Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles | MAP4K2, MAP4K1, MAP4K3 | PRKCQ 210/4885PRKCD 266/4885LYN 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.